Clinical Trials on Stage III Intrahepatic Bile Duct Cancer AJCC v8

Total 1234 results

Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

Glioma | Astrocytoma | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Oligodendroglioma | Recurrent Glioma | Invasive Breast Carcinoma | Breast Carcinoma Metastatic in the Brain

United States
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Completed

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Lung Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Lung Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI); Novartis; National Institutes of Health (NIH); EUSA Pharma, Inc...

Completed

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

United States
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
Roswell Park Cancer Institute
National Cancer Institute (NCI); Novartis

Withdrawn

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Mayo Clinic

Recruiting

Biobank for Cholestatic Liver Diseases.

Cholangiocarcinoma | Primary Sclerosing Cholangitis | Liver Cancer | Primary Biliary Cirrhosis

United States
National Cancer Institute (NCI)

Recruiting

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Platinum-Resistant Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
National Cancer Institute (NCI)

Completed

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Adenocarcinoma | Unresectable Pancreatic Carcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7

United States, Canada
National Cancer Institute (NCI)

Completed

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Advanced Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Advanced Sarcomatoid Renal Cell Carcinoma

United States
Emory University
National Cancer Institute (NCI); Prostate Cancer Foundation

Recruiting

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ROS1 Gene Rearrangement | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | ALK Positive

United States
Mayo Clinic

Recruiting

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Mayo Clinic

Recruiting

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Refractory Malignant Solid Neoplasm | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Recurrent Mantle Cell Lymphoma | Metastatic Lung Non-Small Cell Carcinoma | Refractory Chronic Lymphocytic Leukemia | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Acute Lymphoblastic Leukemia | Metastatic Triple-Negative... and other conditions

United States
National Cancer Institute (NCI)

Completed

3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer (NRG PROMETHEAN)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States, Canada
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Exelixis

Active, not recruiting

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Pancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Pancreatic Acinar Cell Carcinoma | Locally Advanced Pancreatic Adenocarcinoma

United States
Thomas Jefferson University

Recruiting

An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma

United States
Mayo Clinic

Recruiting

Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Stage IA Uterine Corpus Cancer AJCC v8 | Stage IB Uterine Corpus Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

Melanoma | Anatomic Stage III Breast Cancer AJCC v8 | Locally Advanced Breast Carcinoma | Breast Inflammatory Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Recurrent Breast Carcinoma | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER)

Metastatic Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Unclassified Renal Cell Carcinoma | Stage II Renal Cell Cancer AJCC v7

United States, Canada, Israel
Fred Hutchinson Cancer Center
PromiCell Therapeutics, Inc.

Not yet recruiting

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
University of Michigan Rogel Cancer Center

Recruiting

Gilteritinib for the Treatment of ALK NSCLC

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
University of Washington
National Cancer Institute (NCI)

Recruiting

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

Stage IV Prostate Cancer AJCC v8 | Localized Prostate Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Lynch Syndrome | Stage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | DNA Repair Disorder

United States, Puerto Rico, Germany
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Mayo Clinic

Recruiting

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
University of Washington
United States Department of Defense

Recruiting

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institute of Dental and Craniofacial...

Active, not recruiting

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

United States
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Buccal Mucosa Squamous Cell Carcinoma | Floor of Mouth Squamous Cell Carcinoma | Gingival Squamous Cell Carcinoma | Hard Palate Squamous Cell Carcinoma | Lip Squamous Cell... and other conditions

United States, Canada

Clinical Trials on Stage III Intrahepatic Bile Duct Cancer AJCC v8

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations